Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
RANDOMIZED CONTROLLED TRIAL
Loïc Guillevin, Christian Pagnoux, Alexandre Karras, Chahera Khouatra, Olivier Aumaître, Pascal Cohen, François Maurier, Olivier Decaux, Jacques Ninet, Pierre Gobert, Thomas Quémeneur, Claire Blanchard-Delaunay, Pascal Godmer, Xavier Puéchal, Pierre-Louis Carron, Pierre-Yves Hatron, Nicolas Limal, Mohamed Hamidou, Maize Ducret, Eric Daugas, Thomas Papo, Bernard Bonnotte, Alfred Mahr, Philippe Ravaud, Luc Mouthon
BACKGROUND: The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission. METHODS: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive either 500 mg of rituximab on days 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22...
November 6, 2014: New England Journal of Medicine
#2
COMMENT
Ami Schattner
No abstract text is available yet for this article.
June 16, 2015: Annals of Internal Medicine
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
